Cargando…
Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylation
Proteasome inhibitors such as bortezomib are highly active in multiple myeloma by affecting signaling cascades and leading to a toxic buildup of misfolded proteins. Bortezomib-treated cells activate the cytoprotective heat shock response (HSR), including upregulation of heat shock proteins (HSPs). H...
Autores principales: | Shah, Shardule P., Nooka, Ajay K., Jaye, David L., Bahlis, Nizar J., Lonial, Sagar, Boise, Lawrence H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312344/ https://www.ncbi.nlm.nih.gov/pubmed/27487129 http://dx.doi.org/10.18632/oncotarget.10847 |
Ejemplares similares
-
Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone
por: Schmidt, Timothy M., et al.
Publicado: (2019) -
Multiple myeloma immunoglobulin lambda translocations portend poor prognosis
por: Barwick, Benjamin G., et al.
Publicado: (2019) -
Heat shock proteins in multiple myeloma
por: Zhang, Lei, et al.
Publicado: (2014) -
Activation of kinase phosphorylation by heat-shift and mild heat-shock
por: Petrocchi, Pamela, et al.
Publicado: (2010) -
Dexamethasone treatment promotes Bcl-2-dependence in multiple myeloma resulting in sensitivity to Venetoclax
por: Matulis, Shannon M., et al.
Publicado: (2015)